8-K: vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results, Provides Corporate Update

vTv Therapeutics reports its Q4 and full-year 2024 financial results, highlights the lifting of the clinical hold on its cadisegliatin program, and announces a new Chief Commercial Officer.

Summary

• vTv Therapeutics announced its financial results for the fourth quarter and full year ended December 31, 2024.
• The FDA lifted the clinical hold on the cadisegliatin program in March 2025.
• The Phase 3 CATT1 trial in patients with T1D is expected to resume in Q2 2025 with a shortened trial duration.
• Martin Lafontaine has been appointed as Chief Commercial Officer.
• The company's cash position as of December 31, 2024, was $36.7 million, compared to $9.4 million as of December 31, 2023.
• R&D expenses for the year ended December 31, 2024, were $11.5 million, compared to $13.6 million in 2023.
• G&A expenses for the year ended December 31, 2024, were $13.7 million, compared to $11.9 million in 2023.
• Net loss attributable to vTv shareholders for the year ended December 31, 2024, was $18.5 million, or $3.20 per basic share, compared to $20.3 million, or $9.71 per basic share, in the previous year.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the lifting of the clinical hold and the appointment of a new CCO, offset by continued net losses and increased G&A expenses.

Positives

• The FDA lifting the clinical hold on the cadisegliatin program is a major positive development.
• The increase in cash position to $36.7 million provides financial stability for ongoing and future trials.
• The appointment of Martin Lafontaine as CCO strengthens the company's commercial leadership.
• The reduction in net loss from $20.3 million to $18.5 million indicates improved financial performance.

Negatives

• The company continues to experience net losses, with a net loss of $18.5 million for the year ended December 31, 2024.
• G&A expenses increased by $1.7 million for the year ended December 31, 2024, primarily due to increased payroll and share-based expenses.

Risks

• The company's future success is heavily dependent on the successful development and commercialization of cadisegliatin.
• Clinical trials are subject to inherent risks and uncertainties, including the possibility of unfavorable results or delays.
• The company may require additional funding in the future to support its operations and clinical development programs.
• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The company expects to resume its Phase 3 CATT1 trial in patients with T1D in the second quarter of 2025 following submission of a protocol amendment. The company anticipates that subsequent events and developments will cause their views to change.

Management Comments

• 'We are thrilled our cadisegliatin clinical program can resume following the lifting of the clinical hold by the U.S. Food and Drug Administration (FDA).'
• 'We expect to resume our Phase 3 CATT1 trial in patients with T1D in the second quarter of 2025 following submission of a protocol amendment shortening the trial duration from 12 to 6 months,' said Paul Sekhri, Chairman, President and Chief Executive Officer of vTv Therapeutics.
• 'As we approach our next stage of growth, we are pleased to have strengthened our commercial leadership with the appointment of Martin Lafontaine as our Chief Commercial Officer,' said Paul Sekhri.

Industry Context

vTv Therapeutics is focused on developing cadisegliatin as a potential first-in-class oral adjunctive therapy to insulin for type 1 diabetes, a market with significant unmet needs. The appointment of a seasoned commercial executive like Martin Lafontaine suggests the company is preparing for potential commercialization, aligning with industry trends of companies focusing on specialized therapeutic areas.

Comparison to Industry Standards

• Comparing vTv Therapeutics' cash position of $36.7 million to other clinical-stage biopharmaceutical companies of similar size, it appears to be adequate for near-term clinical trial activities.
• Eli Lilly and Company's acquisition of Locemia Solutions Inc. after Martin Lafontaine's instrumental role in developing Nasal Glucagon highlights his experience in successful diabetes-related ventures.
• The reduction in trial duration from 12 to 6 months is a common strategy in clinical development to accelerate timelines and reduce costs, aligning with industry best practices.

Management Changes

Stakeholder Impact

• Shareholders will be impacted by the progress of the cadisegliatin program and the company's financial performance.
• Employees will be affected by the company's strategic direction and operational activities.
• Patients with type 1 diabetes could potentially benefit from the successful development of cadisegliatin.

Next Steps

• Resume the Phase 3 CATT1 trial in Q2 2025.
• Submit a protocol amendment to shorten the CATT1 trial duration.
• Advance the late-stage cadisegliatin program under the leadership of the new CCO.

Key Dates

Keywords

cadisegliatin, type 1 diabetes, T1D, clinical trial, financial results, vTv Therapeutics, CATT1, FDA, clinical hold, Martin Lafontaine, Chief Commercial Officer